Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Recruiting · NCT05423691 · Registry updated 2025-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, blood platelet disease, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2025-04-13 | NCT05423691 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cellenkos, Inc. | 5 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University | New York | United States | 154 |
| Montefiore Einstein Cancer Center | The Bronx | United States | 7 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| UC Davis Health | Sacramento | United States | 23 |